• 1. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 2. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 3. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 4. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin
• 5. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Sulfinylbenzimidazoles

4-Desmethoxypropoxyl-4-chloro Rabeprazole (CAS No. 168167-42-8): A Comprehensive Overview

4-Desmethoxypropoxyl-4-chloro Rabeprazole (CAS No. 168167-42-8) is a chemically modified derivative of Rabeprazole, a well-known proton pump inhibitor (PPI) used in the treatment of gastrointestinal disorders. This compound has garnered significant attention in pharmaceutical research due to its potential therapeutic applications and unique structural properties. In this article, we delve into the chemical characteristics, synthesis, applications, and market trends of 4-Desmethoxypropoxyl-4-chloro Rabeprazole, while addressing common queries and recent advancements in the field.

The molecular structure of 4-Desmethoxypropoxyl-4-chloro Rabeprazole includes a chloro substitution at the 4-position and a desmethoxypropoxyl modification, which differentiates it from its parent compound, Rabeprazole. These alterations may influence its pharmacokinetic and pharmacodynamic properties, making it a subject of interest for researchers exploring novel PPI derivatives. The CAS No. 168167-42-8 serves as a unique identifier for this compound in chemical databases, ensuring accurate referencing in scientific literature.

One of the most frequently asked questions about 4-Desmethoxypropoxyl-4-chloro Rabeprazole is its potential therapeutic benefits. While Rabeprazole is primarily used to treat acid-related disorders such as gastroesophageal reflux disease (GERD) and peptic ulcers, the modified version may offer enhanced stability or targeted action. Researchers are investigating whether the chloro and desmethoxypropoxyl groups could improve bioavailability or reduce side effects, a topic of high relevance in modern drug development.

From a synthetic chemistry perspective, the production of 4-Desmethoxypropoxyl-4-chloro Rabeprazole involves multi-step organic reactions, often starting from Rabeprazole or its precursors. The introduction of the chloro group typically requires halogenation reagents, while the desmethoxypropoxyl modification may involve etherification or other functional group transformations. These processes are crucial for ensuring the purity and efficacy of the final product, a key consideration for pharmaceutical manufacturers.

The applications of 4-Desmethoxypropoxyl-4-chloro Rabeprazole extend beyond its potential as a therapeutic agent. It is also used as a reference standard in analytical chemistry for quality control and method validation. Laboratories employ techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS) to quantify and characterize this compound, ensuring compliance with regulatory standards. This aspect is particularly important for researchers and quality assurance professionals in the pharmaceutical industry.

Market trends indicate a growing demand for specialized PPI derivatives, including 4-Desmethoxypropoxyl-4-chloro Rabeprazole. The global pharmaceutical industry is increasingly focusing on personalized medicine and targeted therapies, driving the need for structurally diverse compounds. Additionally, the rise of generic drug development has spurred interest in modified versions of established drugs, further boosting the relevance of this compound.

Environmental and safety considerations are also critical when working with 4-Desmethoxypropoxyl-4-chloro Rabeprazole. While it is not classified as a hazardous material, proper handling and disposal protocols must be followed to minimize risks. Researchers and manufacturers are encouraged to adhere to Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP) to ensure safety and compliance.

In conclusion, 4-Desmethoxypropoxyl-4-chloro Rabeprazole (CAS No. 168167-42-8) represents a promising area of research in medicinal chemistry. Its unique structural features, potential therapeutic applications, and role as an analytical standard make it a valuable compound in the pharmaceutical and chemical industries. As advancements in drug design and analytical technologies continue, the significance of this derivative is likely to grow, offering new opportunities for innovation and discovery.

• 220757-74-4(4-Desmethoxy-4-chloro Omeprazole Sulfide)
• 110374-16-8(4-Desmethoxy Omeprazole)
• 64588-65-4(1H-BENZIMIDAZOLE, 2-[[(4-CHLORO-2-PYRIDINYL)METHYL]SULFINYL]-)
• 60524-91-6(1H-BENZIMIDAZOLE, 5-METHYL-2-[[(5-METHYL-2-PYRIDINYL)METHYL]SULFINYL]-)
• 1159977-27-1(4-Desmethoxypropoxyl-4-chloro Rabeprazole Sulfone)
• 103312-62-5(4-Desmethoxypropoxyl-4-chloro Rabeprazole Sulfide)
• 60524-78-9(1H-BENZIMIDAZOLE, 4,6-DIMETHYL-2-[(2-PYRIDINYLMETHYL)SULFINYL]-)
• 863029-89-4(4-Desmethoxy-4-chloro Omeprazole)
• 64588-75-6(6-Methyl-2-[(4-methylpyridin-2-yl)methanesulfinyl]-1H-benzimidazole)
• 60524-97-2(1H-BENZIMIDAZOLE, 2-[[(3-METHYL-2-PYRIDINYL)METHYL]SULFINYL]-)